Hypertrophic cardiomyopathy (HCM)
is so much more than a problem with my heart.
It’s giving up my long runs.
It’s having to change careers.
It’s worrying about how to support my family.
HCM is so much more than just a heart problem.
It's a human problem.1
Algenis,
Diagnosed with HCM in 2022
Actual consented patient.
Of the 660,000+ people with HCM in the US, more than 50% remain undiagnosed9*
Thanh,
Diagnosed with HCM in 2023
Actual consented patient.
HCM is a progressive, misdiagnosed, and often overlooked myocardial disorder defined by left ventricular hypertrophy in the absence of any other cause.2-5
~70% of people with HCM have obstructive HCM6†
~30% of people with HCM have nonobstructive HCM6
~60% of people with HCM have recognizable familial disease7
While ~40% of people with HCM have no identified cause, it is one of the most common heritable cardiac disorders7,8
HCM is a progressive, underdiagnosed and often overlooked disease in the United States. We know that it is more common than diagnosed.
Dr. Matthew Martinez, Cardiologist
Diagnostic Challenges
Learn about some common obstacles to an HCM diagnosis and how to overcome them
Exercise Capacity
Learn about peak oxygen consumption (pVO2) as one predictor of mortality in HCM
Whole-Person Care
Find out how a comprehensive care team can make a difference in the lives of people with HCM
*Note: Latest assumptions as of July 2023; data on file.
†Defined as peak left ventricular outflow tract (LVOT) gradient of ≥30 mm Hg.2
References: 1. Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4(1):102. doi:10.1186/s41687-020-00269-8 2. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/cir.0000000000001250 3. Argulian E, Sherrid MV, Messerli FH. Misconceptions and facts about hypertrophic cardiomyopathy. Am J Med. 2016;129(2):148-152. doi:10.1016/j.amjmed.2015.07.035 4. Naidu SS, Sutton MB, Gao W, et al. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2023;26(1):682-690. doi:10.1080/13696998.2023.2208966 5. Maurizi N, Olivotto I, Maron MS, et al. Lifetime clinical course of hypertrophic cardiomyopathy. JACC Adv. 2023;2(4):100337. doi:10.1016/j.jacadv.2023.100337 6. Lu DY, Pozios I, Haileselassie B, et al. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc. 2018;7(5). doi:10.1161/jaha.117.006657 7. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749-770. doi:10.1161/CIRCRESAHA.117.311059 8. Girolami F, Frisso G, Benelli M, et al. Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications. J Cardiovasc Med (Hagerstown). 2018;19(1):1-11. doi:10.2459/JCM.0000000000000589 9. Data on file. Symphony Health 2016-2021 Patient Claims Data. South San Francisco, CA. Cytokinetics, Inc; 2021.